Page last updated: 2024-11-03

propranolol and Brain Hemorrhage, Cerebral

propranolol has been researched along with Brain Hemorrhage, Cerebral in 10 studies

Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.

Research Excerpts

ExcerptRelevanceReference
"Seven patients (4 with subarachnoid hemorrhage, 2 with intracerebral hemorrhage, and 1 with massive cerebral infarction) had acute arterial hypertension refractory to control by several antihypertensive drugs (hydralazine, sodium nitroprusside, alpha-methyldopa, and trimethaphan camsylate) used singly or in combination."5.26Catecholamine-associated refractory hypertension following acute intracranial hemorrhage: control with propranolol. ( Baldwin, CA; Feibel, JH; Joynt, RJ, 1981)
"Propranolol was safe and well tolerated in this population."3.30Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial. ( Al-Shahi Salman, R; Bertani, GA; Dejana, E; Lanfranconi, S; Latini, R; Meessen, JMTA; Pallini, R; Scola, E, 2023)
"Propranolol has recently been shown to be effective in the treatment of infantile hemangioma, a close pathologic counterpart of cavernous malformations."1.43Propranolol Treatment of Cavernous Malformations with Symptomatic Hemorrhage. ( Filippidis, AS; Kalani, MYS; Spetzler, RF; Zabramski, JM, 2016)
"The tremor was refractory to pharmacotherapy (clonazepam, propranolol, and levodopa), but was reduced after implantation of a thalamic stimulator device."1.30Midbrain tremor and hypertrophic olivary degeneration after pontine hemorrhage. ( Bakke, SJ; Nyberg-Hansen, R; Shepherd, GM; Tauböll, E, 1997)
"Seven patients (4 with subarachnoid hemorrhage, 2 with intracerebral hemorrhage, and 1 with massive cerebral infarction) had acute arterial hypertension refractory to control by several antihypertensive drugs (hydralazine, sodium nitroprusside, alpha-methyldopa, and trimethaphan camsylate) used singly or in combination."1.26Catecholamine-associated refractory hypertension following acute intracranial hemorrhage: control with propranolol. ( Baldwin, CA; Feibel, JH; Joynt, RJ, 1981)

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19903 (30.00)18.7374
1990's1 (10.00)18.2507
2000's1 (10.00)29.6817
2010's4 (40.00)24.3611
2020's1 (10.00)2.80

Authors

AuthorsStudies
Lanfranconi, S3
Scola, E3
Meessen, JMTA3
Pallini, R3
Bertani, GA3
Al-Shahi Salman, R3
Dejana, E3
Latini, R3
Zan, J1
Song, L1
Wang, J1
Zou, R1
Hong, F1
Zhao, J1
Cheng, Y1
Xu, M1
Yamada, H1
Kikuchi, R1
Katayama, J1
Nakamura, A1
Miyazaki, H1
Zabramski, JM1
Kalani, MYS1
Filippidis, AS1
Spetzler, RF1
Esparza, EM1
Deutsch, G1
Stanescu, L1
Weinberger, E1
Brandling-Bennett, HA1
Sidbury, R1
Oh, SJ1
Hong, YK1
Song, EK1
Feibel, JH1
Baldwin, CA1
Joynt, RJ1
Shepherd, GM1
Tauböll, E1
Bakke, SJ1
Nyberg-Hansen, R1
Ram, Z1
Spiegelman, R1
Findler, G1
Hadani, M1
Hunt, D1
Gore, I1

Trials

1 trial available for propranolol and Brain Hemorrhage, Cerebral

ArticleYear
Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial.
    The Lancet. Neurology, 2023, Volume: 22, Issue:1

    Topics: Cerebral Hemorrhage; Female; Hemangioma, Cavernous, Central Nervous System; Humans; Male; Middle Age

2023
Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial.
    The Lancet. Neurology, 2023, Volume: 22, Issue:1

    Topics: Cerebral Hemorrhage; Female; Hemangioma, Cavernous, Central Nervous System; Humans; Male; Middle Age

2023
Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial.
    The Lancet. Neurology, 2023, Volume: 22, Issue:1

    Topics: Cerebral Hemorrhage; Female; Hemangioma, Cavernous, Central Nervous System; Humans; Male; Middle Age

2023
Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial.
    The Lancet. Neurology, 2023, Volume: 22, Issue:1

    Topics: Cerebral Hemorrhage; Female; Hemangioma, Cavernous, Central Nervous System; Humans; Male; Middle Age

2023
Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial.
    The Lancet. Neurology, 2023, Volume: 22, Issue:1

    Topics: Cerebral Hemorrhage; Female; Hemangioma, Cavernous, Central Nervous System; Humans; Male; Middle Age

2023
Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial.
    The Lancet. Neurology, 2023, Volume: 22, Issue:1

    Topics: Cerebral Hemorrhage; Female; Hemangioma, Cavernous, Central Nervous System; Humans; Male; Middle Age

2023
Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial.
    The Lancet. Neurology, 2023, Volume: 22, Issue:1

    Topics: Cerebral Hemorrhage; Female; Hemangioma, Cavernous, Central Nervous System; Humans; Male; Middle Age

2023
Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial.
    The Lancet. Neurology, 2023, Volume: 22, Issue:1

    Topics: Cerebral Hemorrhage; Female; Hemangioma, Cavernous, Central Nervous System; Humans; Male; Middle Age

2023
Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial.
    The Lancet. Neurology, 2023, Volume: 22, Issue:1

    Topics: Cerebral Hemorrhage; Female; Hemangioma, Cavernous, Central Nervous System; Humans; Male; Middle Age

2023

Other Studies

9 other studies available for propranolol and Brain Hemorrhage, Cerebral

ArticleYear
Role of ghrelin in small intestinal motility following pediatric intracerebral hemorrhage in mice.
    Molecular medicine reports, 2017, Volume: 16, Issue:5

    Topics: Animals; Atropine; Cerebral Hemorrhage; Disease Models, Animal; Down-Regulation; Enzyme-Linked Immun

2017
Paroxysmal Sympathetic Hyperactivity after Surgery for Cerebral Hemorrhagic Arteriovenous Malformation: A Case Report.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2018, Volume: 27, Issue:10

    Topics: Adolescent; Adrenergic beta-Antagonists; Amines; Autonomic Nervous System Diseases; Brain Injuries;

2018
Propranolol Treatment of Cavernous Malformations with Symptomatic Hemorrhage.
    World neurosurgery, 2016, Volume: 88

    Topics: Adrenergic beta-Antagonists; Adult; Brain Neoplasms; Cerebral Hemorrhage; Female; Hemangioma, Cavern

2016
Multifocal lymphangioendotheliomatosis with thrombocytopenia: phenotypic variant and course with propranolol, corticosteroids, and aminocaproic acid.
    Journal of the American Academy of Dermatology, 2012, Volume: 67, Issue:1

    Topics: Aminocaproates; Cerebral Hemorrhage; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Inf

2012
Paroxysmal autonomic dysregulation with fever that was controlled by propranolol in a brain neoplasm patient.
    The Korean journal of internal medicine, 2007, Volume: 22, Issue:1

    Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Autonomic Nervous System Diseases; Body Temperatur

2007
Catecholamine-associated refractory hypertension following acute intracranial hemorrhage: control with propranolol.
    Annals of neurology, 1981, Volume: 9, Issue:4

    Topics: Adult; Aged; Antihypertensive Agents; Cerebral Hemorrhage; Epinephrine; Female; Humans; Hypertension

1981
Midbrain tremor and hypertrophic olivary degeneration after pontine hemorrhage.
    Movement disorders : official journal of the Movement Disorder Society, 1997, Volume: 12, Issue:3

    Topics: Adrenergic beta-Antagonists; Anticonvulsants; Antiparkinson Agents; Cerebral Hemorrhage; Clonazepam;

1997
Delayed postoperative neurological deterioration from prolonged sodium nitroprusside administration. Case report.
    Journal of neurosurgery, 1989, Volume: 71, Issue:4

    Topics: Brain Edema; Cerebral Hemorrhage; Coma; Craniotomy; Cyanides; Ferricyanides; Hematoma; Humans; Hyper

1989
Myocardial lesions following experimental intracranial hemorrhage: prevention with propranolol.
    American heart journal, 1972, Volume: 83, Issue:2

    Topics: Animals; Cerebral Hemorrhage; Electrocardiography; Heart; Heart Ventricles; Male; Myocardial Infarct

1972